top of page

MENU

  • AutorenbildJuergen Mairhofer

enGenes Biotech reaches proof-of-concept for -exPAND bioreactor scale non-canonical amino acid incorporation process

enGenes Biotech reaches proof-of-concept for -exPAND bioreactor scale non-canonical amino acid incorporation process

News-ReleasesEnGenes Biotech GmbH

April 14th 2020

Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) has reached successful proof-of-concept for bioreactor scale incorporation of non-canonical amino acid into antibody mimetic.

This proprietary -eXPAND process is scalable and delivers ~250 mg/L labeled antibody mimetic that can be selectively modified by dual labelling at a C-terminal cysteine and a non-canonical amino acid incorporated at a specific site.

Advanced bioconjugation solution

The -eXPAND project, commenced in 2018, was developed in collaboration with acib GmbH with funding from the Austrian Research Promotion Agency (FFG) in the BRIDGE program.

The -eXPAND approach allows, for example, labelling of an antibody fragment or affibody/nanobody with a drug payload and a fluorophore for detection and visualization. It is thus highly relevant for companies seeking solutions in the field drug development and bioconjugation.



Comments


bottom of page